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detected more frequently in APS patients, but 
the prevalence of aPE was higher among patients 
without concomitant APS. The presence of aPS 
and aPE was generally not related to the presence 
of other types of autoantibodies. The authors ob-
served myocardial infarction, Raynaud phenom-
enon, and thrombocytopenia more often in sub-
jects with positive aPS in the IgM class. Moreover, 
the elevated levels of aPE in the IgM class were 
associated with a decreased risk of proteinuria. 
The data on the prevalence of aPS and aPE 
among patients with SLE and APS presented by 
Butkiewicz et al.1 are consistent with previous 
studies; however, the authors did not confirm 
some of the associations found by other inves-
tigators. They refer to the paper by Sciascia et 
al.2 claiming that aPS were included in the set 
of aPL used in the global anti-phospholipid syn-
drome score used to validate the risk of throm-
bosis and pregnancy loss in SLE patients. Howev-
er, Sciascia et al.2 included the antibodies direct-
ed against antiphosphatidylserine–prothrombin 
complex (aPS/PT) and not aPS.
The issue raised by Butkiewicz et al.1 may con-
tribute to the discussion on the so called sero-
negative APS, wherein the clinical symptoms are 
highly suggestive of APS but consensus antibod-
ies are persistently negative. We also emphasized 
the usefulness of determining nonconventional 
aPL in patients with autoimmune diseases when 
APS is suspected.3 It has been shown in other 
studies that aCL crossreact with other antibod-
ies to negatively charged phospholipids and are 
unlikely to become independent markers of APS. 
Butkiewicz et al.1 also mention the coexistence 
of aPS with aCL in patients with secondary APS. 
Sciascia et al.4 reported the diagnostic accuracy of 
aPS/PT for APS as a whole and for both thrombo-
sis and pregnancy loss. They concluded that add-
ing aPS/PT to LAC and anti-β2GPI improves the 
To the Editor We read with great interest an ar-
ticle by Butkiewicz et al.1 reporting associations 
between the presence of antiphosphatidyloser-
ine antibodies (aPS) and antiphosphatidyloeth-
anolamine antibodies (aPE) and the clinical pre-
sentation of systemic lupus erythematosus (SLE). 
The authors studied 71 patients with SLE in com-
parison with 36 volunteers without autoimmune 
diseases. To determine the levels of aPS and aPE 
immunoglobulin (Ig) G and IgM classes, the au-
thors used commercially available double-anti-
body enzyme-linked immunosorbent assays by 
DEMEDITEC Diagnostics GmbH, Kiel-Wellsee, 
Germany, and The Binding Site Inc., San Diego, 
United States, respectively. The serum concen-
trations of aPS/aPE of 10 IU/ml or higher were 
considered positive. Data on clinical manifesta-
tions of SLE and treatment for all patients were 
obtained from medical records reviewed from 
1990 until 2010. The presence of antinuclear an-
tibodies, anticardiolipin antibodies (aCL), lupus 
anticoagulant (LAC), antiprothrombin antibod-
ies, and anti-β2 glycoprotein I (anti-β2GPI) anti-
bodies was also verified retrospectively. As for 
clinical symptoms, the authors considered the de-
scriptors of the Systemic Erythematosus Disease 
Activity Index (SLEDAI) and many other mani-
festations. Moreover, in all patients, erythrocyte 
sedimentation rate, C-reactive protein, complete 
blood count, and echocardiography were assessed. 
There were no significant differences in the de-
mographic characteristics between the groups. Of 
note, the prevalence of hypertension was high-
er in patients compared with controls (43.7% vs 
5.0%). Secondary antiphospholipid syndrome 
(APS) was present only in 38% of patients with 
SLE. Positive aPE were more prevalent in the 
study group than positive aPS, whereas in con-
trols, only aPE in the IgM class were detected al-
though less frequently than in patients. aPS were 
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diagnostic power and helps better stratify the 
risk of thrombosis and pregnancy morbidity. 
Thus, aPS/PT have been included, among other 
variables, into 2 scoring systems: the aPL score 
and the global anti-phospholipid syndrome score. 
Butkiewicz et al.1 did not confirm a higher in-
cidence of thromboembolic events in aPS-posi-
tive subjects. However, the presence of aPS in 
the IgM class increased the risk of myocardial 
infarction, with no effect on the occurrence of 
ischemic heart disease. They do not report any 
associations between the studied antibodies and 
pregnancy morbidity. It would be interesting to 
know the incidence of the latter manifestation of 
APS in their study group. In other studies some 
associations were found between aPS, especial-
ly of the IgG class, and pregnancy loss.5 Finally, 
the authors did not report any significant asso-
ciations between aPE and clinical manifestations 
of SLE,  and those observed for aPS were weak 
and probably did not have any significant im-
pact on the course of SLE. It might be interest-
ing to study the associations between other an-
tibodies such as the aPS/PT complex, antiphos-
phatidylinositol, antiphosphatidic acid, or anti-
prothrombin and clinical symptoms of SLE in a 
larger group of patients.
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